Researchers identify a new mechanism for the regulation of blood pressure.

Researchers at the RIKEN Brain Science Institute have uncovered a new mechanism for the regulation of blood pressure. The new study links events at the single-cell level to a system-level effect, showing that blood pressure can drop dramatically if the protein ERAP1 is released from cells and enters the blood stream.  Because high blood pressure is a primary risk factor for stroke, heart disease, and diabetes, understanding how the human body naturally regulates blood pressure is essential for developing treatments that help keep it at normal levels.  The opensource study is published in Molecular Cell.

Towards this end, the team began their investigation when they saw that mice lacking the protein ERp44 had lower than normal blood pressure.  The researchers noticed that the mice had similar defects to those that lack angiotensin II, the peptide hormone that acts to raise blood pressure.  The group measured the animal’s blood pressure and were surprised to find it was about 20% lower than in normal mice.

The current study showed that angiotensin II, a peptide hormone vital for maintaining blood pressure, in these ERp44 knockout mice was removed from circulation faster than in normal mice, explaining the drop in blood pressure. ERp44 is a multi-functional protein located in the endoplasmic reticulum, the place where proteins are folded into their proper shapes before being released into the rest of a cell. To determine why angiotensin II did not remain in the blood of these mice, researchers searched for proteins that bind to ERp44 inside cells and are also able to leave cells and enter the blood stream where they can interact with angiotensin.

The data findings showed that the enzyme ERAP1, an aminopeptidase whose job is to cleave peptides like angiotensin, normally binds to ERp44 when the oxygen level inside of the endoplasmic reticulum is high and is released into the blood when the endoplasmic reticulum environment is reducing, that is when oxygen is low. Without any ERp44, the results showed that all the ERAP1 in the knockout mice was free to enter the blood stream where it digested angiotensin II, resulting in lower than normal blood pressure in the knockout mice.

The current study showed that oxygen levels in the endoplasmic reticulum can fluctuate depending on several factors, including cellular stress. When stress causes the oxygen levels in the endoplasmic reticulum to drop, ERAP1 is released, and blood pressure is lowered to maintain balance.

Conversely, the research team also discovered that the amount of cellular Erp44 increases when a system-wide infection causes blood pressure to drop dangerously low. This increase creates more opportunities for ERAP1 to bind, and reduces its chance of getting into the blood stream. The net result is that angiotensin remains in the blood to prevent the pressure from dropping even lower.

The team state that the discovery could also have implications for the control of high blood pressure. Angiotensin II is produced from precursor peptides when low blood pressure triggers a series of events in the renin-angiotensin system, and the majority of drugs that combat high blood pressure target the enzymes that are involved in this process.

The researchers state that current therapies for hypertension target the enzyme that produces angiotensin II.  The team conclude that the results open the door to alternative approaches that target the activity of proteins like ERAP1 and ERp44 and hope their results can lead to the development of new strategies for treating people with blood-pressure disorders.

Source:  RIKEN Brain Science Institute

Blood pressure maintenance is vital for systemic homeostasis, and angiotensin II is a critical regulator. The upstream mechanisms that regulate angiotensin II are not completely understood. Here, we show that angiotensin II is regulated by ERp44, a factor involved in disulfide bond formation in the ER. In mice, genetic loss of ERp44 destabilizes angiotensin II and causes hypotension. We show that ERp44 forms a mixed disulfide bond with ERAP1, an aminopeptidase that cleaves angiotensin II. ERp44 controls the release of ERAP1 in a redox-dependent manner to control blood pressure. Additionally, we found that systemic inflammation triggers ERAP1 retention in the ER to inhibit hypotension. These findings suggest that the ER redox state calibrates serum angiotensin II levels via regulation of the ERp44-ERAP1 complex. Our results reveal a link between ER function and normotension and implicate the ER redox state as a potential risk factor in the development of cardiovascular disease.  ERp44 Exerts Redox-Dependent Control of Blood Pressure at the ER.  Mikoshiba  et al 2015.
Blood pressure maintenance is vital for systemic homeostasis, and angiotensin II is a critical regulator. The upstream mechanisms that regulate angiotensin II are not completely understood. Here, we show that angiotensin II is regulated by ERp44, a factor involved in disulfide bond formation in the ER. In mice, genetic loss of ERp44 destabilizes angiotensin II and causes hypotension. We show that ERp44 forms a mixed disulfide bond with ERAP1, an aminopeptidase that cleaves angiotensin II. ERp44 controls the release of ERAP1 in a redox-dependent manner to control blood pressure. Additionally, we found that systemic inflammation triggers ERAP1 retention in the ER to inhibit hypotension. These findings suggest that the ER redox state calibrates serum angiotensin II levels via regulation of the ERp44-ERAP1 complex. Our results reveal a link between ER function and normotension and implicate the ER redox state as a potential risk factor in the development of cardiovascular disease. ERp44 Exerts Redox-Dependent Control of Blood Pressure at the ER. Mikoshiba et al 2015.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.